Evidence map›Paper›PMID 30972279›Full record

ArticleActa pharmaceutica Sinica. B2019

The epigallocatechin gallate derivative Y

Yan Wen, Ruiqiang Zhao, Pranav Gupta, Yingfang Fan, Yunkai Zhang, Zhenguang Huang, Xiaohui Li, Yuangang Su, Lijuan Liao, Yu-An Xie and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Epigallocatechin Gallate Derivative YRecent patents on anti-cancer drug discovery · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Yan WenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John׳s University, Queens, NY 11439, USA.
Ruiqiang ZhaoDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John׳s University, Queens, NY 11439, USA.
Pranav GuptaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John׳s University, Queens, NY 11439, USA.
Yingfang FanDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John׳s University, Queens, NY 11439, USA.
Yunkai ZhangDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John׳s University, Queens, NY 11439, USA.
Zhenguang HuangDepartment of Pharmacy, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Xiaohui LiDepartment of Biotechnology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
Yuangang SuDepartment of Biotechnology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
Lijuan LiaoDepartment of Biotechnology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
Yu-An XieThe Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Donghua YangDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John׳s University, Queens, NY 11439, USA.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John׳s University, Queens, NY 11439, USA.
Gang LiangCollege of Pharmacy, Guangxi Medical University, Nanning 530021, China.
Guangxi Medical University · CNSt. John's University · USTumor Hospital of Guangxi Medical University · CNZhujiang Hospital · CN

Funding

Targeting MRP7 to Overcome Drug Resistance for Ovarian Cancer Therapy by TaxanesR15CA143701 · NCI · ST. JOHN'S UNIVERSITY · PI CHEN, ZHE-SHENG · 2010 to 2010
$245k
NCI NIH HHS R15 CA143701
6 · The paper itself

Abstract

Previously, we reported that Y

Indexed as

5,3′,4′,3″,4″,5″-6-O-ethyl-EGCG (Y6)ABCB1Drug resistanceEpigallocatechin gallate (EGCG)P-gpResistance reversal

Identifiers

PMID30972279
PMCPMC6437594
OpenAlexW2897458303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.